A RANDOMIZED, DOUBLE-BLIND, CLINICAL-TRIAL OF TOPICAL CLOTRIMAZOLE VERSUS MICONAZOLE FOR TREATMENT OF CUTANEOUS LEISHMANIASIS IN THE EASTERN PROVINCE OF SAUDI-ARABIA

The parenteral treatment currently available for cutaneous leishmanias is (CL) is painful and potentially exposes patients to serious side ef fects. Thus, effective, topical therapy would be valuable. We assessed the efficacy of topical 1% clotrimazole and 2% miconazole creams in r elation to early healing of lesions in CL in a randomized, double-blin d clinical trial in 54 patients with 151 lesions treated for 30 consec utive days. Response to treatment was assessed at two weeks and 30 day s and classified as fully healed, size reduced, no change, and size in creased or worse. Of 89 lesions treated with clotrimazole, 14 (15.7%) healed fully, 42 (47.2%) were reduced in size, 20 (22.5%) showed no ch ange, and 13 (14.6%) got worse. Correspondingly, in the 62 lesions tre ated with miconazole, none healed fully, 22 (35.5%) were reduced in si ze, 16 (25.8%) showed no change, and 24 (38.7%) got worse. The differe nces were statistically significant (P < 0.001). No side effects were observed. It is concluded that clotrimazole was the more effective of the two imidazoline compounds and is recommended as initial treatment for simple lesions.